

TRIAMCINOLONE ACETONIDE 15G

DESCRIPTION

The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. Triamcinolone acetonide is a member of this class. Chemically triamcinolone acetonide is pregna-1, 4-diene-3, 20-dione, 9-flouro-11, 21-dihydroxy-16, 17-[(1-methylethylidene)bis(oxy)]-(11 β 16a). Its structural formula is:



Each gram of Triamcinolone Acetonide Cream USP, 0.025 % contains 0.25 mg triamcinolone acetonide USP in a cream base consisting of purified water, emulsifying wax, mineral oil, propylene glycol, sorbitol solution, cetyl palmitate, sorbic acid, and potassium sorbate.

Each gram of Triamcinolone Acetonide Cream USP, 0.1 % contains 1 mg triamcinolone acetonide USP in a cream base consisting of purified water, emulsifying wax, mineral oil, propylene glycol, sorbitol solution, cetyl palmitate, sorbic acid, and potassium sorbate.

Each gram of Triamcinolone Acetonide Cream USP, 0.5 % contains 5 mg triamcinolone acetonide USP in a cream base consisting of purified water, emulsifying wax, mineral oil, propylene glycol, sorbitol solution, cetyl palmitate, sorbic acid, and potassium sorbate.

CLINICAL PHARMACOLOGY

Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. Pharmacokinetics

The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the

percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses. (See *DOSAGE AND ADMINISTRATION*) Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteriods are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

INDICATIONS & USAGE

Triamcinolone acetonide cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

CONTRAINDICATIONS

Triamcinolone acetonide cream is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

PRECAUTIONS

GENERAL PRECAUTIONS

Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.

Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.

Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.

Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids. Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (See *PRECAUTIONS-Pediatric Use*).

If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted. In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

INFORMATION FOR PATIENTS

Patients using topical corticosteroids should receive the following information and instructions.

- 1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
- 2. Patients should be advised not to use this medication for any disorder other than for which it was prescribed.
- 3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician.
- 4. Patients should report any signs of local adverse reactions especially under occlusive dressing.
- 5. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.

LABORATORY TESTS

The following tests may be helpful in evaluating the HPA axis suppression: Urinary free cortisol test ACTH stimulation test

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY

Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids.

Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.

PREGNANCY CATEGORY C

Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are not adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

NURSING MOTHERS

It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.

PEDIATRIC USE

Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppressionand Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio.

Hypothalamic- pituitary-adrenal (HPA) axis suppression, Cushings's syndrome and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.

Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.

ADVERSE REACTIONS

The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence:

Burning Itching Irritation Dryness Folliculitis Hypertrichosis Acneiform eruptions Hypopigmentation Perioral dermatitis Allergic contact dermatitis Maceration of the skin Secondary infection Skin Atrophy Striae Miliaria

OVERDOSAGE

Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (See PRECAUTIONS).

DOSAGE & ADMINISTRATION

Topical corticosteroids are generally applied to the affected area as a thin film from two to three times daily depending on the severity of the condition. Occlusive dressing may be used for the management of psoriasis or recalcitrant conditions.

If an infection develops, the use of occlusive dressing should be discontinued and appropriate antimicrobial therapy instituted.

HOW SUPPLIED

Triamcinolone acetonide cream USP 0.1% is supplied in

30 GRAM in a TUBE (0440-0251-30) 45 GRAM in a JAR (0440-0251-45) 80 GRAM in a TUBE (0440-0251-80) 15 GRAM in a TUBE (0440-0251-15)

Store at 20-25°C (68°-77°F) [see USP Controlled Room Temperature]. Avoid excessive heat. Protect from freezing.

PRINTED IN USA

Packaged by: AIDAREX PHARMACEUTICALS LLC.

CORONA, CA 92880.

Revised: 07/2016

PACKAGE LABEL. PRINCIPAL DISPLAY PANEL

	NDC: 00	narmaceuticals Inc. 0440-0251-15 NE ACETONIDE, US RAND NAME: KENALOG		ACKAGED BY: AIDAREX PHARMACEUTICALS LLC CORONA, CA 92880 THIS PRODUCT WAS PRODUCED FOR U.S. GOVERNMENT MEDICAL FACILITIES ONLY. COMMERCIAL USE IS PROHIBITED.		
	0.1%	15 GM/ TUBE		DOCTOR	DATE	
	EACH GRAM CONTAINS THE FOLLOWING ACTIVE INGREDIENTS:	15 GM/ TUBE		CREAM		
	LOT:	EXP DATE:	=	APPLY	TIMES DAILY	
а М		IES, INC. JOHNSON CITY, TN 37604	CAUTI	E PACKAGE INSERT. KEEP O	TS DISPENSING WITHOUT PRESCRIPT UT OF REACH OF CHILDREN. STORE P CONTROLLED ROOM TEMP].	

30 GRAMS LABEL DISPLAY

	LIBERTY Pharmaceuticals Inc. NDC: 00440-0251-30 TRIAMCINOLONE ACETONIDE, USP GENERIC FOR BRAND NAME: KENALOG			PACKAGED BY: AIDAREX PHARMACEUTICALS LLC CORONA, CA 92880 THIS PRODUCT WAS PRODUCED FOR U.S. GOVERNMENT MEDICAL FACILITIES ONLY. COMMERCIAL USE IS PROHIBITED.		
	0.1%	30 GM/ TUBE		DOCTOR	DATE	
<u> </u>	EACH GRAM CONTAINS THE FOLLOWING ACTIVE INGREDIENTS: ACETONIDE 1MG			c	REAM	
in de la companya de La companya de la comp	LOT:	EXP DATE:	_	APPLY	TIMES DAILY	
	IFG: CROWN LABORATOR	IES, INC. JOHNSON CITY, TN 37604	CAUT		BITS DISPENSING WITHOUT PRESCRIPTIO OUT OF REACH OF CHILDREN. STORE ISP CONTROLLED ROOM TEMP].	

80 GRAMS LABEL DISPLAY

RX ONLY		armaceuticals Inc. 0440-0251-80	PACK	CORO	PHARMACEUTICALS LLC NA, CA 92880 AS PRODUCED FOR
		NE ACETONIDE, US	Р		T MEDICAL FACILITIES AL USE IS PROHIBITED.
	0.1%	80 GM/ TUBE		DOCTOR	DATE
NA KANCASTRUCTOCIALINA NA	EACH GRAM CONTAINS THE FOLLOWING ACTIVE INGREDIENTS:	TRIAMCINOLONE ACETONIDE 1MG		CF	REAM
3	LOT:	EXP DATE:		APPLY	TIMES DAILY
		ES, INC. JOHNSON CITY, TN 37604	SEEF	PACKAGE INSERT. KEEP OU	S DISPENSING WITHOUT PRESCRIPTION. T OF REACH OF CHILDREN. STORE CONTROLLED ROOM TEMP].
454 GRA	MS LABEL DISPLAY				
454 GRA		armaceuticals Inc.	PACK	AGED BY: AIDAREX	PHARMACEUTICALS LLC
	LIBERTY Ph	armaceuticals Inc. 0440-0251-45	PACK	CORO	NA, CA 92880
	LIBERTY Ph NDC: 00 TRIAMCINOLO			CORO THIS PRODUCT W U.S. GOVERNMEN	
	LIBERTY Ph NDC: 00 TRIAMCINOLO GENERIC FOR B	0440-0251-45 NE ACETONIDE, US		CORO THIS PRODUCT W U.S. GOVERNMEN	NA, CA 92880 AS PRODUCED FOR T MEDICAL FACILITIES AL USE IS PROHIBITED.
	LIBERTY Ph NDC: 00 TRIAMCINOLO	0440-0251-45 NE ACETONIDE, US		CORO THIS PRODUCT W U.S. GOVERNMEN ONLY. COMMERC	NA, CA 92880 AS PRODUCED FOR T MEDICAL FACILITIES AL USE IS PROHIBITED.
	LIBERTY Ph NDC: 00 TRIAMCINOLO GENERIC FOR B	0440-0251-45 NE ACETONIDE, US		CORO THIS PRODUCT W U.S. GOVERNMEN ONLY. COMMERC DOCTOR PATIENT: CF	NA, CA 92880 AS PRODUCED FOR T MEDICAL FACILITIES AL USE IS PROHIBITED.

MFG: CROWN LABORATORIES, INC. JOHNSON CITY, TN 37604

CAUTION: FEDERAL LAW PROHIBITS DISPENSING WITHOUT PRESCRIPTION. SEE PACKAGE INSERT. KEEP OUT OF REACH OF CHILDREN. STORE AT 20-25C (68-77F) [SEE USP CONTROLLED ROOM TEMP].

PACKAGE LABEL. PRINCIPAL DISPLAY PANEL

	LIBERTY Pharmaceuticals Inc. NDC: 00440-0251-30 TRIAMCINOLONE ACETONIDE, USI GENERIC FOR BRAND NAME: KENALOG			PACKAGED BY: AIDAREX PHARMACEUTICALS LLC CORONA, CA 92880 THIS PRODUCT WAS PRODUCED FOR U.S. GOVERNMENT MEDICAL FACILITIES ONLY. COMMERCIAL USE IS PROHIBITED.			
COLUMNERS.	0.1%	30 GM/ TUBE			DATE		
III NEO IGAN CANTHOLAN CONTRACTOR NA III	EACH GRAM CONTAINS THE FOLLOWING ACTIVE INGREDIENTS:	TRIAMCINOLONE ACETONIDE 1MG		CF	REAM		
5	LOT:	EXP DATE:	_	APPLY	TIMES DAILY		
		S, INC. JOHNSON CITY, TN 3760	OCO	PACKAGE INSERT. KEEP OU	S DISPENSING WITHOUT PRESCRIPTION. IT OF REACH OF CHILDREN. STORE CONTROLLED ROOM TEMP].		
PACKA RX ONLY	LIBERTY Pha	PAL DISPLAY PANEL armaceuticals Inc. 440-0251-80	PACI	CORO	PHARMACEUTICALS LLC NA, CA 92880 AS PRODUCED FOR		
		GENERIC FOR BRAND NAME: KENALOG			T MEDICAL FACILITIES AL USE IS PROHIBITED.		
and house characterized in the	0.1%	80 GM/ TUBE		DOCTOR	DATE		
NUMBER OF	EACH GRAM CONTAINS THE FOLLOWING ACTIVE INGREDIENTS:	TRIAMCINOLONE ACETONIDE 1MG		CF	REAM		
5	LOT:	EXP DATE:	_	APPLY	TIMES DAILY		
1499 BAN II	MFG: CROWN LABORATORIES, INC. JOHNSON CITY, TN 37604			PACKAGE INSERT. KEEP OU	S DISPENSING WITHOUT PRESCRIPTION. T OF REACH OF CHILDREN. STORE CONTROLLED ROOM TEMP].		

PACKAGE LABEL. PRINCIPAL DISPLAY PANEL

	TRIAM G O. EACH GRAM O THE FOLLOWI INGREDIENTS LOT:	NDC: 00 CINOLON EENERIC FOR BF 1%	Armaceuticals Inc. 440-0251-45 NE ACETONIDE, U RAND NAME: KENALOG 454 GM/ JAR TRIAMCINOLONE ACETONIDE 1MG EXP DATE: ES, INC. JOHNSON CITY, TN 376	SP]	THIS PF U.S. GC ONLY. (DOCTO PATIEN AF CAUTION: FEDERAL SEE PACKAGE IN	RODU VER COM IT: PPLN		PRODUCED F MEDICAL FACII USE IS PROH	OR LITIES IBITED.
_									
	RIAMCINOL		TONIDE						
tria	mcinolone acetor	nde cream							
P	roduct Informat	tion							
Pr	oduct T ype		HUMAN PRESCRIPTION DRUG	Ite m	Code (Sour	ce)	NDC:044	40-0251(NDC:6	7877-251)
Ro	oute of Administra	tion	TOPICAL						
Δ	ctive Ingredient	t/Active Moi	atv						
11	cuve ingreatent		gredient Name]	Basis of	Strength	Strength
		C ETO NIDE (UNI	: F446C597KA) (TRIAMCINOLO)	NE ACI	ETONIDE -		AMCINOL	ONE	1 mg in 1 g
	III:F446C597KA)					ACI	ETONIDE		
In	active Ingredie	nts							
			Ingredient Name					Stren	gth
	NERAL OIL (UNII: 7		10 7372)						
	OPYLENE GLYCO RBITOL (UNII: 506		10 / ¥ 3 J						
	TYL PALMITATE (8X)						
	RBIC ACID (UNII: X		•						
РО	TASSIUM SORBAT	FE (UNII: 1VPU26	JZZ4)						
W	ATER (UNII: 059QF0	KO0R)							
n	alvaging								
Ра #	nckaging Item Code	1	Package Description		Mankating	Sto	rt Data	Markoting	End Data
	NDC:0440-0251-15		Type 0: Not a Combination Produ	ict	Marketing 0 4/0 1/20 12	Std	It Date	Marketing	Enu Date
	NDC:0440-0251-13	_	; Type 0: Not a Combination Prod		04/01/2012				
	NDC:0440-0251-50	_	ype 0: Not a Combination Produc		04/01/2012				
		. , -	••						

Marketing Information								
Marketing Category								
ANDA	ANDA088042	0 4/0 1/20 12						

Labeler - Liberty Pharmaceuticals, Inc. (012568840)

Revised: 7/2016

Liberty Pharmaceuticals, Inc.